Shortcomings in the technical documentation of mesh implants intended to treat pelvic organ prolapse used in the Netherlands After a detailed assessment of the technical documentation of 9 different mesh implants intended to treat pelvic organ prolapse used in NL (2018) RIVM concludes that the safety and performance of these products were not properly substantiated.
Better monitoring of RSV thanks to new European project RIVM and Nivel contribute to building a European RSV monitoring network. Through the network, European health institutions and laboratories will exchange data on the spread of RSV. This will help us to better monitor the virus.
More reports of adverse effects of implants in 2019 In 2019, the Dutch reporting centre for adverse effects of medical implants (MEBI) received 397 reports of suspected adverse effects. The reports concerned 462 implants.
Mesh implants intended to treat pelvic organ prolapse Synthetic mesh are used to treat patients with pelvic organ prolapse.
Control measures against the spread of Legionella from wastewater treatment plants Wastewater treatment plants (WWTPs) may spread Legionella via the air and cause pneumonia if people inhale them.
Slightly fewer adult smokers In 2018, 22.4 per cent of the Dutch adult population indicated they were occasional smokers.
Young people who use screens before sleeping have more sleep problems Young people (13-18 years) who use light-emitting screens daily in the hour before going to sleep have more sleep problems.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).